Skip to main content

Keros Therapeutics Inc

For the period ended Dec 31, 2024. Filed Feb 26, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 26, 2025

KROS$9.17-2.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Keros Therapeutics, Inc.
Date: February 26, 2025By:/s/ Jasbir Seehra
Jasbir Seehra, Ph.D.
Chief Executive Officer
(Principal Executive Officer)

POWER OF ATTORNEY AND SIGNATURES

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jasbir Seehra, Ph.D., and Keith Regnante, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

NAMETITLEDATE
/s/ Jasbir SeehraChief Executive Officer and Director(Principal Executive Officer)February 26, 2025
Jasbir Seehra, Ph.D.
/s/ Keith RegnanteChief Financial Officer(Principal Financial Officer and Principal Accounting Officer)February 26, 2025
Keith Regnante
/s/ Jean-Jacques BienaiméDirectorFebruary 26, 2025
Jean-Jacques Bienaimé
/s/ Nima FarzanDirectorFebruary 26, 2025
Nima Farzan
/s/ Carl GordonDirectorFebruary 26, 2025
Carl Gordon, Ph.D., C.F.A.
/s/ Mary Ann GrayDirectorFebruary 26, 2025
Mary Ann Gray, Ph.D.
/s/ Tomer KarivDirectorFebruary 26, 2025
Tomer Kariv
/s/ Julius KnowlesDirectorFebruary 26, 2025
Julius Knowles
/s/ Ran NussbaumDirectorFebruary 26, 2025
Ran Nussbaum
/s/ Alpna SethDirectorFebruary 26, 2025
Alpna Seth, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.